Want to see GB:CTG full AI Analyst Report?
Top Page
Christie
(LSE:CTG)
Select Model
Select Model
Rating:67Neutral
Price Target:
195.00 p
▲(20.00% Upside)
Action:Reiterated
Date:08/26/26
The score is primarily driven by improving financial momentum and strong cash flow recovery, tempered by historically volatile profitability and a leveraged balance sheet. Technicals are supportive with the price above key moving averages and positive MACD, while valuation (moderate P/E and a ~2.3% yield) and positive corporate developments provide additional support.
Positive Factors
Revenue and profit rebound
The recovery in both revenue and net income indicates renewed demand across Christie’s specialist services and improved operating performance. If maintained, this stronger earnings base can support reinvestment and improve financial resilience over the next several quarters.
Negative Factors
High financial leverage
Debt materially exceeds equity, leaving Christie with less balance-sheet flexibility than a lightly leveraged services company. This structure can constrain investment and increase vulnerability if earnings weaken, particularly given the company’s history of uneven profitability.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue and profit rebound
The recovery in both revenue and net income indicates renewed demand across Christie’s specialist services and improved operating performance. If maintained, this stronger earnings base can support reinvestment and improve financial resilience over the next several quarters.
Read all positive factors
Christie (CTG) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£45.84M
Dividend Yield1.94%
Average Volume (3M)24.61K
Price to Earnings (P/E)12.7
Beta (1Y)0.24
Revenue Growth19.99%
EPS Growth79.90%
CountryUK
Employees651
SectorIndustrials
Sector Strength72
IndustrySpecialty Business Services
Share Statistics
EPS (TTM)0.14
Shares Outstanding26,526,728
10 Day Avg. Volume20,568
30 Day Avg. Volume24,611
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)5.98
Price to Sales (P/S)0.45
P/FCF Ratio4.61
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.14
Revenue Forecast (FY)£75.00M
Christie Business Overview & Revenue Model
Company Description
Christie Group plc is a well-established provider of professional services, operating across Europe and internationally. The company serves a diverse range of industries including hospitality, leisure, healthcare, medical, childcare, education, an...
Christie Financial Statement Overview
Summary
Income Statement
62
Positive
Balance Sheet
48
Neutral
Cash Flow
70
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 71.81M | 70.60M | 60.39M | 52.34M | 69.19M | 61.25M |
| Gross Profit | 7.93M | 70.60M | 2.00M | 14.77M | 5.22M | 2.58M |
| EBITDA | 9.69M | 8.83M | 3.94M | -1.25M | 7.25M | 6.94M |
| Net Income | 3.76M | 3.40M | 536.00K | -3.80M | 3.21M | 3.58M |
Balance Sheet | ||||||
| Total Assets | 32.89M | 34.38M | 29.51M | 29.45M | 36.44M | 36.94M |
| Cash, Cash Equivalents and Short-Term Investments | 8.70M | 9.40M | 4.87M | 1.34M | 8.84M | 8.17M |
| Total Debt | 8.93M | 9.48M | 8.71M | 10.34M | 11.65M | 12.23M |
| Total Liabilities | 26.80M | 29.02M | 24.40M | 26.15M | 28.04M | 35.38M |
| Stockholders Equity | 6.08M | 5.36M | 5.11M | 3.30M | 8.40M | 1.56M |
Cash Flow | ||||||
| Free Cash Flow | 5.14M | 6.96M | 2.23M | -4.38M | 4.39M | 1.80M |
| Operating Cash Flow | 5.60M | 7.47M | 2.73M | -3.46M | 5.18M | 2.34M |
| Investing Cash Flow | -280.00K | -1.24M | 2.55M | -797.00K | -787.00K | -487.00K |
| Financing Cash Flow | -1.58M | -1.70M | -1.66M | -3.32M | -3.71M | -3.21M |
Christie Technical Analysis
Neutral
162.50
Price Trends
167.25
Positive
153.63
Positive
143.08
Positive
Market Momentum
3.76
Positive
55.45
Neutral
40.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:CTG, the sentiment is Neutral. The current price of 162.5 is below the 20-day moving average (MA) of 185.23, below the 50-day MA of 167.25, and above the 200-day MA of 143.08, indicating a neutral trend. The MACD of 3.76 indicates Positive momentum. The RSI at 55.45 is Neutral, neither overbought nor oversold. The STOCH value of 40.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GB:CTG.
Christie Peers Comparison
UnderperformOutperform
Sector (63)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | £2.66B | 32.51 | 15.86% | 2.14% | 10.55% | -19.05% | |
68 Neutral | £9.03B | 28.29 | 29.86% | 2.80% | 3.94% | -8.14% | |
68 Neutral | £2.42B | 16.25 | 17.55% | 1.86% | 1.20% | 221.80% | |
67 Neutral | £45.84M | 12.75 | 65.79% | 1.94% | 19.99% | 79.90% | |
63 Neutral | $10.79B | 15.43 | 7.44% | 2.01% | 2.89% | -14.66% | |
62 Neutral | £7.52B | 21.19 | 5.82% | 3.14% | -0.18% | 39.04% |
* Industrials Sector Average
GB:CTG
Christie
180.00
70.37
64.19%
GB:ITRK
Intertek
5,885.00
1,039.51
21.45%
GB:MTO
Mitie Group plc
210.00
76.92
57.80%
GB:RTO
Rentokil Initial
299.00
-107.16
-26.38%
GB:SRP
Serco Group plc
249.80
14.70
6.25%
Christie Corporate Events
Business Operations and StrategyFinancial Disclosures
Christie Group Flags Surge in Pubs and Restaurants Deals and Values
Positive
Oct 6, 2026
Christie Group’s agency and advisory arm, Christie Co, has released its 2026 Pubs Restaurants Market Review, highlighting a marked rise in deal activity and transaction values across the sector despite ongoing cost pressures and shifting c...
Business Operations and StrategyFinancial Disclosures
Christie & Co’s 2026 Review Shows Strong UK Pharmacy Deal Activity and Rising Margins
Positive
Oct 1, 2026
Christie Group’s agency and advisory business Christie Co has released its Pharmacy Market Review 2026, highlighting robust activity and improving financial performance in the UK pharmacy sector. The firm leverages its brokerage, valuation ...
Business Operations and StrategyDividendsFinancial DisclosuresM&A Transactions
Christie Group lifts interim dividend as profits and deal pipeline strengthen
Positive
Sep 28, 2026
Christie Group reported a 5.4% rise in first-half 2026 revenues to £36.0m, driven by growth across all five trading brands in both UK and international markets, with underlying operating profit up 11.1% and margins improving despite higher st...
Business Operations and StrategyFinancial Disclosures
Christie & Co Report Points to Strong UK Care-Sector Deal Activity
Positive
Sep 24, 2026
Christie Group’s specialist agency and advisory arm, Christie Co, has published its Care Market Review 2026, signalling a robust UK care sector after a record £12 billion of transactions in 2025 and strong ongoing interest from both do...
Business Operations and StrategyProduct-Related Announcements
Christie Group launches revamped website to support growth and investor outreach
Positive
Sep 22, 2026
Christie Group plc, a London-listed provider of professional and financial services as well as stock and inventory systems to sectors including healthcare, hospitality and retail, has launched a new corporate website. The platform consolidates inf...
Business Operations and Strategy
Christie & Co report shows resilient demand in UK convenience and forecourt retail
Positive
Sep 16, 2026
Christie Group’s agency and advisory arm, Christie Co, has published its Retail Market Review 2026, analysing transaction activity, buyer demand, trading conditions, regulation and emerging opportunities across UK convenience store and fore...
Business Operations and StrategyFinancial Disclosures
Christie Group sets date for interim results and investor presentation
Neutral
Sep 15, 2026
Christie Group plc will release its interim results for the six months ended 30 June 2026 on 28 September 2026, underscoring a key reporting milestone for the AIM-quoted business services provider. The announcement will give investors updated visi...
Business Operations and Strategy
Christie Group Highlights Strengthening UK Dental Market in 2026 Review
Positive
Sep 8, 2026
Christie Group’s agency and advisory arm, Christie Co, has released its Dental Market Review 2026, offering a detailed assessment of the UK dental sector based on transactional data, sentiment surveys and advisory work, alongside lending an...
Business Operations and StrategyExecutive/Board Changes
Christie Group Adds Christie & Co Chief Darren Bond to Board
Positive
Sep 7, 2026
Christie Group plc has strengthened its board with the appointment of Darren Bond, Global Managing Director of Christie Co, as an Executive Director with immediate effect. Bond brings extensive experience in valuation, brokerage, consultancy and ...
Business Operations and Strategy
Christie & Co expands market-leading dental brokerage into Republic of Ireland
Positive
Aug 4, 2026
Christie Group’s agency and advisory arm, Christie Co, has launched a dedicated dental brokerage service in the Republic of Ireland, extending its UK-leading dental advisory operation into a new European market. The move brings its speciali...
Business Operations and Strategy
Christie Group Highlights Strong Deal Activity in UK Day Nurseries with 2026 Market Review
Positive
Jul 13, 2026
Christie Group’s agency and advisory arm, Christie Co, has released its Day Nurseries Market Review 2026, offering a detailed assessment of the UK children’s day nurseries sector, including occupancy trends, fee growth, margins, inves...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.